Femoral Versus Nonfemoral Subclavian/Carotid Arterial Access Route for Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
20 10 2020
Historique:
pubmed: 30 9 2020
medline: 16 3 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

Background Some concerns remain regarding the safety of transcarotid and transsubclavian approaches for transcatheter aortic valve replacement. We aimed to compare the risk of 30-day complications and death in transcarotid/transsubclavian versus transfemoral transcatheter aortic valve replacement recipients. Methods and Results Data from 20 studies, including 79 426 patients (16 studies) and 3992 patients (4 studies) for the evaluation of the unadjusted and adjusted impact of the arterial approach were sourced, respectively. The use of a transcarotid/transsubclavian approach was associated with an increased risk of stroke when using unadjusted data (risk ratio [RR], 2.28; 95% CI, 1.90-2.72) as well as adjusted data (odds ratio [OR], 1.53; 95% CI, 1.05-2.22). The pooled results deriving from unadjusted data showed an increased risk of 30-day death (RR, 1.46; 95% CI, 1.22-1.74) and bleeding (RR, 1.53; 95% CI, 1.18-1.97) in patients receiving transcatheter aortic valve replacement through a transcarotid/transsubclavian access (compared with the transfemoral group), but the associations between the arterial access and death (OR, 1.22; 95% CI, 0.89-1.69), bleeding (OR, 1.05; 95% CI, 0.68-1.61) were no longer significant when using adjusted data. No significant effect of the arterial access on vascular complication was observed in unadjusted (RR, 0.84; 95% CI, 0.66-1.06) and adjusted (OR, 0.79; 95% CI, 0.53-1.17) analyses. Conclusions Transcarotid and transsubclavian approaches for transcatheter aortic valve replacement were associated with an increased risk of stroke compared with the transfemoral approach. However, these nonfemoral arterial alternative accesses were not associated with an increased risk of 30-day death, bleeding, or vascular complication when taking into account the confounding factors.

Identifiants

pubmed: 32990146
doi: 10.1161/JAHA.120.017460
pmc: PMC7792420
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e017460

Références

Circ Cardiovasc Interv. 2010 Aug;3(4):359-66
pubmed: 20606135
J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230
pubmed: 27956264
Eur J Cardiothorac Surg. 2019 Dec 1;56(6):1140-1146
pubmed: 31365061
J Am Coll Cardiol. 2019 Sep 24;74(12):1532-1540
pubmed: 31537261
Eur J Cardiothorac Surg. 2011 Jul;40(1):49-55
pubmed: 21232969
J Am Coll Cardiol. 2011 Jan 18;57(3):253-69
pubmed: 21216553
Ann Thorac Surg. 2015 Nov;100(5):1718-26; discussion 1726-7
pubmed: 26233276
J Am Coll Cardiol. 2019 Dec 3;74(22):2728-2739
pubmed: 31779788
JACC Cardiovasc Interv. 2011 Aug;4(8):851-8
pubmed: 21851897
EuroIntervention. 2020 Jun 25;16(3):266-268
pubmed: 31793886
EuroIntervention. 2018 Sep 20;14(7):750-757
pubmed: 29969427
J Am Heart Assoc. 2020 Oct 20;9(19):e017460
pubmed: 32990146
Circ Cardiovasc Interv. 2018 Nov;11(11):e006388
pubmed: 30571205
J Am Coll Cardiol. 2012 Aug 7;60(6):502-7
pubmed: 22726631
Eur Heart J. 2011 Jan;32(2):191-7
pubmed: 20843959
Circulation. 2017 Sep 5;136(10):e172-e194
pubmed: 28784624
JACC Cardiovasc Interv. 2018 Jul 9;11(13):1311-1312
pubmed: 29976369
J Am Coll Cardiol. 2017 Jan 31;69(4):465-466
pubmed: 28126163
JACC Cardiovasc Interv. 2016 Mar 14;9(5):472-80
pubmed: 26965937
J Cardiovasc Med (Hagerstown). 2015 Apr;16(4):271-8
pubmed: 25036268
Circ J. 2018 Sep 25;82(10):2518-2522
pubmed: 30068794
JACC Cardiovasc Interv. 2019 Mar 11;12(5):448-456
pubmed: 30846083
EuroIntervention. 2017 Mar 20;12(16):1954-1961
pubmed: 27746402
Clin Res Cardiol. 2013 Sep;102(9):627-36
pubmed: 23666543
Expert Rev Med Devices. 2019 Jan;16(1):11-24
pubmed: 30526139
Int J Cardiol. 2013 Sep 30;168(2):1034-40
pubmed: 23164594
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
J Cardiovasc Med (Hagerstown). 2015 Apr;16(4):279-85
pubmed: 25689087
J Thorac Cardiovasc Surg. 2020 Apr 13;:
pubmed: 32387164
N Engl J Med. 2012 May 3;366(18):1705-15
pubmed: 22551129
EuroIntervention. 2020 Nov 20;16(10):842-849
pubmed: 32310129
Am J Cardiol. 2015 Nov 15;116(10):1555-9
pubmed: 26409640
Ann Thorac Cardiovasc Surg. 2018 Jun 20;24(3):161-164
pubmed: 29628466
J Thromb Thrombolysis. 2013 May;35(4):456-62
pubmed: 23143652
J Am Coll Cardiol. 2018 Jan 2;71(1):101-102
pubmed: 29301616
Ann Thorac Surg. 2018 Oct;106(4):1105-1112
pubmed: 29758214
PLoS One. 2013 Dec 26;8(12):e83138
pubmed: 24386151
Ann Thorac Surg. 2018 Feb;105(2):477-483
pubmed: 29100645
JACC Cardiovasc Interv. 2019 Apr 8;12(7):662-669
pubmed: 30947940
JACC Cardiovasc Interv. 2017 Dec 11;10(23):2414-2422
pubmed: 29217004
J Am Coll Cardiol. 2017 Jul 4;70(1):42-55
pubmed: 28662806
Curr Cardiol Rep. 2016 Nov;18(11):110
pubmed: 27650782
Arch Cardiovasc Dis. 2020 Mar;113(3):189-198
pubmed: 32037133

Auteurs

Laurent Faroux (L)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Lucia Junquera (L)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Siamak Mohammadi (S)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

David Del Val (D)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Guillem Muntané-Carol (G)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Alberto Alperi (A)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Dimitri Kalavrouziotis (D)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Eric Dumont (E)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Jean-Michel Paradis (JM)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Robert Delarochellière (R)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Josep Rodés-Cabau (J)

Quebec Heart and Lung InstituteLaval University Quebec City Quebec Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH